Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Soluble CD40L (CD154) is increased in patients with shock.

Chew, Michelle LU ; Rahman, Milladur LU orcid ; Ihrman, L ; Erson, A ; Zhang, S and Thorlacius, Henrik LU (2010) In Inflammation Research 59. p.979-982
Abstract
OBJECTIVE: Recent data suggest that soluble CD40L (sCD40L) plays an important role in murine sepsis. The aim of the present study was to determine plasma levels of CD40L in critically ill patients with systemic inflammatory response syndrome (SIRS) and shock, with and without sepsis. DESIGN: A prospective observational one-centre cohort study in a mixed-bed ICU of an university hospital. Fifty-three consecutive patients fulfilling the criteria for SIRS with shock as well as seven age-matched controls were included. ELISA was used to determine sCD40L in the plasma. RESULTS: The level of sCD40L in plasma from healthy controls was 0.18 +/- 0.03 ng/ml. It was found that sCD40L levels were significantly higher in patients with non-septic shock... (More)
OBJECTIVE: Recent data suggest that soluble CD40L (sCD40L) plays an important role in murine sepsis. The aim of the present study was to determine plasma levels of CD40L in critically ill patients with systemic inflammatory response syndrome (SIRS) and shock, with and without sepsis. DESIGN: A prospective observational one-centre cohort study in a mixed-bed ICU of an university hospital. Fifty-three consecutive patients fulfilling the criteria for SIRS with shock as well as seven age-matched controls were included. ELISA was used to determine sCD40L in the plasma. RESULTS: The level of sCD40L in plasma from healthy controls was 0.18 +/- 0.03 ng/ml. It was found that sCD40L levels were significantly higher in patients with non-septic shock (0.72 +/- 0.18 ng/ml) and septic shock (0.50 +/- 0.1 ng/ml). However, the levels of sCD40L were not different between these two groups of patients, or in those with low and high APACHE scores. CONCLUSION: Our data show that sCD40L is increased in patients with shock from septic and non-septic etiologies. However, further studies are needed to delineate the functional significance of sCD40L in the clinical outcome in shock patients. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Inflammation Research
volume
59
pages
979 - 982
publisher
Birkhäuser Verlag
external identifiers
  • wos:000282218900010
  • pmid:20490890
  • scopus:78651320487
  • pmid:20490890
ISSN
1420-908X
DOI
10.1007/s00011-010-0213-5
language
English
LU publication?
yes
id
420ae01f-5fc6-4c1f-9e93-5113587ea0b1 (old id 1610048)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20490890?dopt=Abstract
date added to LUP
2016-04-04 08:53:55
date last changed
2022-04-15 21:02:07
@article{420ae01f-5fc6-4c1f-9e93-5113587ea0b1,
  abstract     = {{OBJECTIVE: Recent data suggest that soluble CD40L (sCD40L) plays an important role in murine sepsis. The aim of the present study was to determine plasma levels of CD40L in critically ill patients with systemic inflammatory response syndrome (SIRS) and shock, with and without sepsis. DESIGN: A prospective observational one-centre cohort study in a mixed-bed ICU of an university hospital. Fifty-three consecutive patients fulfilling the criteria for SIRS with shock as well as seven age-matched controls were included. ELISA was used to determine sCD40L in the plasma. RESULTS: The level of sCD40L in plasma from healthy controls was 0.18 +/- 0.03 ng/ml. It was found that sCD40L levels were significantly higher in patients with non-septic shock (0.72 +/- 0.18 ng/ml) and septic shock (0.50 +/- 0.1 ng/ml). However, the levels of sCD40L were not different between these two groups of patients, or in those with low and high APACHE scores. CONCLUSION: Our data show that sCD40L is increased in patients with shock from septic and non-septic etiologies. However, further studies are needed to delineate the functional significance of sCD40L in the clinical outcome in shock patients.}},
  author       = {{Chew, Michelle and Rahman, Milladur and Ihrman, L and Erson, A and Zhang, S and Thorlacius, Henrik}},
  issn         = {{1420-908X}},
  language     = {{eng}},
  pages        = {{979--982}},
  publisher    = {{Birkhäuser Verlag}},
  series       = {{Inflammation Research}},
  title        = {{Soluble CD40L (CD154) is increased in patients with shock.}},
  url          = {{http://dx.doi.org/10.1007/s00011-010-0213-5}},
  doi          = {{10.1007/s00011-010-0213-5}},
  volume       = {{59}},
  year         = {{2010}},
}